Progenity Stock

Progenity Net Debt/FCF

Delisted

The Net Debt to Free Cash Flow Ratio of Progenity (PROG) as of Aug 14, 2026 is -0.23. In the previous year, Net Debt to Free Cash Flow Ratio was -0.41 — a change of -45.13% (higher).

Net Debt/FCF

-0.23

YoY

-45.13%

Last updated:

Net Debt to Free Cash Flow Ratio of Progenity is 2026 -0.23 . Net Debt to Free Cash Flow Ratio of Progenity was 2025 -0.41 . It decreases by -45.13% higher compared to the previous year.
Access this data via the Eulerpool API

Progenity Stock analysis

What does Progenity do? Progenity Inc. is an American company specializing in the development and marketing of diagnostic tests and genetic screening solutions. It was founded in 2012 and is headquartered in San Diego, California. Progenity is a leading provider of prenatal screening and diagnostic solutions. The company offers a wide range of tests that help expectant parents identify potential health risks for their unborn child. Progenity's prenatal screening palette includes tests for determining chromosomal abnormalities, genetic disorders, and other health risks. A major advantage of these tests is that they are non-invasive, meaning that no dangerous invasive procedures need to be performed. Another important division of Progenity focuses on gastrointestinal health, where the company offers various diagnostic tests to identify and treat gastrointestinal diseases early. This includes tests for detecting colon cancer as well as genetic tests that indicate an increased risk for familial colon cancer syndromes. Progenity also has a division that focuses on cardiovascular diseases. Here, they offer genetic tests, among other things, to determine the risk of heart disease. In addition, the company offers a wide range of diagnostic solutions for general health, such as tests for identifying infectious diseases like HIV or HPV. Progenity also offers its customers various screening and diagnostic tests tailored to specific target groups. This includes tests for women seeking fertility treatment, as well as tests aiming to identify specific hereditary diseases related to cancer or other conditions. To provide customers with the best possible solutions, Progenity utilizes state-of-the-art technologies and innovative methods. The company is a leader in the application of liquid biopsy tests, an innovative method for identifying cancer cells in the blood. For a long time, Progenity has worked closely with leading US health authorities and is accredited by CLIA, the Clinical Laboratory Improvement Amendments. This means that the company operates in accordance with established standards and best practices and can provide its customers with accurate and reliable diagnostic solutions. In recent years, Progenity has experienced an impressive growth rate and has become a recognized provider of diagnostic solutions with a wide range of tests covering various areas of health. The company is committed to providing customers with the best possible solutions to promote their health and well-being. Progenity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Progenity stock

Net Debt to Free Cash Flow Ratio of Progenity is -0.23 in 2026.

Net Debt to Free Cash Flow Ratio of Progenity changed from -0.41 to -0.23, representing a -45.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Progenity since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Progenity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Progenity

All Key Metrics — Progenity